Capabilities that accelerate discovery and unlock new possibilities

Our Discovery Capabilities

We work across two core areas to unlock new possibilities in early-stage drug discovery — supporting partners through high-impact services while advancing our own innovation and internal pipeline in high-value, underserved disease areas.

Drug Discovery Enablement

Faster, smarter services for pharmaceutical and biotechnology teams

MassAffinity offers a set of specialised products and services to help drug discovery teams tackle their most pressing early-stage discovery challenges — especially where traditional methods fall short. Whether you are working with complex diseases, AI-generated hits or undruggable targets, our platform delivers speed, clarity, and confidence.

Deconvolution of Mechanism of Action

Understand why your drug works

We produce key insights on biological pathways that are driving drug efficacy in real biological systems.

PhenoMAP

Hit and Lead Identification in Multifactorial Disease

Find new hits for complex diseases

We discover meaningful interactions across multiple pathways where single-target tools fall short.

TargetMAP

Hit Identification for Undruggable Targets

Unlock targets that traditional tools can’t touch

We screen diverse compound libraries in native environments to identify binding molecules where purification and assays fail.

BinderMAPTargetMAP

Rapid Validation of AI-Generated Hits

Validate your AI-generated predictions in real biology

We validate predicted compound-target interactions quickly and directly, helping AI-driven discovery teams move with confidence.

BinderMAP

Broadening the Lead Series

Expand your lead series, fast

We screen additional compounds to expand and strengthen your early-stage pipeline with confidence.

BinderMAPTargetMAP

Accelerating Hit Identification

Move forward without purification or assays

We bypass major bottlenecks and reach high-confidence hits in weeks — not months.

TargetMAP

Therapeutic Advancement & Discovery

Our internal focus on unlocking complex and underserved 
disease areas

Alongside our partner services, we invest in advancing our own IP and early-stage pipeline in areas where traditional tools have failed. Our goal is to build new pathways to treatment — starting with diseases that lack investment, clarity or both.

This work reflects our belief in a systems-level approach to treating complex, underserved conditions.

Platform advancement

Continual development of new tools, models, frameworks and thinking to help understand complexity in drug discovery and reframe how it works in biologically complex systems.

Systems Biology Innovation

Developing new tools and therapeutic approaches for diseases driven by multiple, interacting biological pathways where single-target methods often fall short.

Multifactorial Disease Discovery

Advancing drug discovery tools that enable more targeted, patient-specific treatments by uncovering how compounds interact in real biological contexts.

Precision & Personalised Medicine

Therapeutic advancement

Targeting under-researched, unmet diseases such as endometriosis using CARMS to better understand disease mechanisms and uncover novel treatment opportunities.

Women's Health

Exploring CNS targets in conditions such as Alzheimer’s and Parkinson’s, using biologically relevant screening to uncover hits that matter.

Neurodegenerative Diseases

Advancing a pipeline of innovative therapeutics in multifactorial conditions, women’s health and neurological health, offering co-development and partnering opportunities at various stages of discovery.

Pipeline development & partnering opportunities

Our pipeline

Advancing treatments in high-need, underexplored areas

We’re actively building a pipeline of internal research programs focused on complex, underserved diseases. Our emerging pipeline targets key areas including neurological health, women’s health and multifactorial conditions.

Asset Indication Target ID Target Validation Hit ID Hit-to-Lead Clinical Trials Regulatory Approval Market Release
MA112 Endometriosis
(Undisclosed Target)
MA113 Endometriosis
(Undisclosed Target)
MAXXX Women's Health
(Multifactorial Target Discovery)
MA112
Endometriosis (Undisclosed Target)
Target ID Target validation Hit ID Hit-to-Lead Clinical Trials Regulatory Approval Market Release
MA113
Endometriosis (Undisclosed Target)
Target ID Target validation Hit ID Hit-to-Lead Clinical Trials Regulatory Approval Market Release
MAXXX
Women’s Health (Multifactorial Discovery)
Target ID Target validation Hit ID Hit-to-Lead Clinical Trials Regulatory Approval Market Release